Introduction
Kidney transplantation (KTx) from deceased or living related donor is the most desired treatment for patients with end-stage renal disease (ESRD) [1] . Due to modern immunosuppression, particularly calcineurin inhibitors, improved surgical techniques and postoperative care the short-term allograft survival increased [2] . However, long term outcomes have not improved to an equal extent and remain challenging for transplant physicians [3] . A major cause of late graft loss is chronic allograft injury (CAI) [4] . It is an incompletely understood condition characterized clinically by gradual deterioration of graft function, often associated with increasing proteinuria and arterial hypertension [5] . The main histological feature of CAI is interstitial fibrosis and tubular atrophy (IFTA) which can be classified as mild, moderate or severe (grade I, II or III) according to Banff grading system [6, 7] . It was found that CAI, fibrosis and atrophy in protocolar biopsies are associated with subclinical rejection [8] . The other leading cause of premature graft loss is BK virus (BKV) nephropathy, which is characterized by inflammatory interstitial nephropathy [9] . It is associated with the necessity of usage of higher doses of immunosuppressants, mainly in the first year after transplantation, and it affects up to 10% of kidney graft recipients [10] . There are no antiviral agents with strong evidence for treatment of BKV infection. The usual strategy upon identification of BKV is gradual reduction of immunosuppression [11, 12] .
Currently, renal biopsy is the gold standard in the assessment of kidney function [13] .
Protocol biopsies performed 3 months and 12 months postoperatively, as a part of standard post-transplant management, are considered to be safe procedures with major complications risk rate from 0.33% to 1% [14, 15] . They have been applied in this setting because clinical signs and symptoms of renal allograft dysfunction (such as creatinine increase or proteinuria) manifest relatively late, although underlying pathology is already advanced [16] . Early detection of active inflammatory processes may lead to optimization of immunosuppressive therapy and improvement of long-term outcomes [17] . Unfortunately, biopsy is an invasive procedure, contraindicated in some patients and cannot be performed repetitively. Therefore, monitoring the progression of injury and inflammation is limited [18] . Urine biomarkers are believed to be promising, non-invasive tools, useful for an early detection and evaluation of allograft dysfunction [19] . Urine seems to be the most attractive specimen as it is easily accessible and directly indicates real-time condition of the kidney [20] .
Chemokines CCL2, also called monocyte chemoattractant protein-1 (MCP-1) and CXCL10 -interferon-γ-induced protein of 10 kDa, are small proteins involved in alloimmune response to kidney allograft injury [21] .
CCL2 is produced in the kidney by mesangial, tubular epithelial and infiltrating inflammatory cells [22] . It acts by binding to the C-C chemokine receptor 2 (CCR2) [23] . CCL2 plays an important role in chemoattraction of monocytes, lymphocytes T and natural killer cells, and also in generation and function of memory CD8+ T cells [24, 25] .
CXCL10 is secreted in response to IFN-g by variety of cells including leukocytes and kidney mesangial cells [26] . It binds to CXCR3 receptor that is located on the immune cells, especially T cells, which results in their recruitment into the allograft and amplification of immune reaction [27] . CXCL10 seems to be crucial in the immune response to the transplanted organ. As Hancock et al. showed, CXCR3−/− mice in comparison to CXCR3+/+ mice present a delay or even an absence of acute or chronic rejection of cardiac graft, and that anti-CXCR3 monoclonal antibody is able to stop the development of rejection [28] .
The aim of this prospective study was to assess whether urine concentrations of chemokines CCL2 and CXCL10 can be valuable, non-invasive source of information about ongoing damaging processes such as interstitial fibrosis and tubular atrophy, BKV nephropathy or mild inflammatory lesions fulfilling the criteria for mild rejection processes or borderline lesions in the kidney allograft.
Patients and Methods

Patient Population
In this study, 40 patients from our transplant center who underwent a protocolar biopsy after 12 months post deceased-donor kidney transplant from 2015 to 2017 were included. On the day of biopsy, the patients were in good health condition and did not have any signs of acute infection (C-reactive protein within normal range). The biopsy procedure was done under ultrasound guidance, using an 18-gauge biopsy needle. Specimens were assessed according to the Banff classification by one renal pathologist [7] .
On the basis of the biopsy results the research group has been selected, and it consists of patients (N=25) with findings such as IFTA II or III (N=16), BKV nephropathy (N=4), or mild inflammatory lesions fulfilling the criteria for mild rejection processes or borderline lesions (N=11). Patients with normal biopsy results were considered as a control group (N=15). Kidney recipients with IFTA I (N=9) were included in the control group as mild IFTA representing natural course of transplant lesions in renal allograft one-year posttransplant. [29, 30] . All patients were of white ethnicity and received tacrolimus, mycophenalate mophetil and steroids as a maintenance immunosuppressive treatment.
The study was approved by the local ethics committee of the Medical University of Warsaw.
All participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki.
Chemokines Analysis
In all the patients the urinary concentrations of chemokines CCL2 and CXCL10 were assayed and expressed with reference to creatinine in urine to correct for urinary dilution [31] . Urine samples were collected at the day of biopsy and stored at -80°C for future analysis.
Chemokines were detected and quantified by enzyme-linked immunosorbent assay (ELISA), according to the instructions provided by the manufacturer (R&D systems, Abingdon, United
Kingdom). Samples were tested in duplicate for each patient and the mean value was used for analysis. The CCL2 and CXCL10 intra-assay, inter-assay coefficients of variation were 5.9%, 5.9% and 3.1%, 9.8%, respectively. The detection limits for ELISAs were 1.7 pg/ml for CCL2 and 1.67 pg/ml for CXCL10.
Statistical Analysis
R software was used for statistical analysis. Categorical data were described as number (%) and continuous data were expressed as mean values with standard deviation (SD) or median with quartiles 1 and 3 (Q1-Q3). Chi-square test or Fisher exact test were used for categorical variables and 2-sample t-test or Mann Whitney U-test for continuous variables. The normality of distribution was assessed by Shapiro-Wilk test. Correlations were determined using Spearman rank correlation coefficient.
The predictive value of urinary chemokine-to-creatinine ratio for occurrence of pathological features in biopsy results (IFTA grade II or III, BKV nephropathy, mild inflammatory lesions) was tested using a univariate and multivariate logistic regression model. Urinary chemokine CCL2-to-creatinine ratio (CCL2:Cr) and urinary chemokine CXCL10-to-creatinine ratio (CXCL10:Cr) were included as covariates in the multivariate model. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. P values less than 0.05 were considered as significant. Table 1 shows patient's characteristics. In all of the patients, biopsy was done 12 months post deceased donor kidney transplant. There was no statistical difference between the research and the control group regarding age, sex, immunologic features (first transplantation, human leukocyte antigen (HLA) mismatch) and blood concentration of tacrolimus at the time of biopsy. Patients in the research group had significantly higher concentration of serum creatinine, urinary albumin-to-creatinine ratio and IFTA grade. Estimated glomerular filtration rate (eGFR) was calculated using CKD-EPI creatinine equation and it was significantly lower in research population. Table 2 includes urinary chemokine-to-creatinine ratios among study groups. CCL2:Cr was significantly higher in research group compared to control group. CXCL10:Cr was increased only in patients diagnosed with BKV nephropathy.
Results
Correlations between urinary chemokines and renal function parameters and total HLA mismatch in study population are depicted in Table 3 . CCL2:Cr was associated with serum creatinine and total HLA mismatch and it was inversely associated with eGFR. There was no correlation between CCL2 and urinary albumin-to-creatinine ratio. CXCL10:Cr was inversely associated with eGFR and associated with urinary albumin-to-creatinine ratio and total HLA mismatch. No association of CXCL10:Cr with serum creatinine concentration was found. All determined correlations were of weak strength.
To assess the prognostic value of CCL2:Cr and CXCL10:Cr of biopsy findings such as IFTA II-III, BKV nephropathy or mild inflammatory lesions, univariate logistic regression analysis was performed (Table 4) . CCL2:Cr turned out to be a significant predictor for BKV nephropathy with OR 1.08; 95% CI 1.02-1.15; p=0.02. CXCL10:Cr was identified as a significant predicting variable of BKV nephropathy (OR 1.16; 95% CI 1.02-1.31; p=0.02).
Both urinary chemokine-to-creatinine ratios were unable to predict the IFTA II-III or suspicious of rejection.
In the second step, multivariate testing was done. It has revealed that CCL2:Cr is a significant independent predictor of BKV nephropathy (OR 1.1 95% CI 1.0-1.2; p=0.04). CXCL10:Cr cannot be considered to predict BKV nephropathy independently (OR 1.3; 95% CI 0.99-1.71; p=0.06).
Discussion
Management of immunosuppression in kidney transplant recipient is a challenging task for a physician. Overimmunosuppression may compromise immune system significantly, leading to, for example, BKV infection, cytomegalovirus infection or increase malignancy risk, whereas not sufficient dose of immunosuppressants can trigger organ rejection [32] . Balance is needed and identification of fast tools for assessment of the immune system status would improve the patient care. The utility of different urinary and serum biomarkers, including chemokines CCL2 and CXCL10, is broadly analyzed [33, 34] .
In our study, urinary CCL2-to-creatinine ratio is highly elevated in the research group and corresponds with pathological changes in kidney graft. It correlates with renal function: serum creatinine and eGFR, but not albuminuria. Correlation with HLA mismatch was observed. It seems to be rational as more mismatches are associated with more rejection episodes, which demands aggressive immunosuppressive therapy that, in turn, may raise the risk of infection and cancer, as human immune system becomes unstable [35] . It is known that BK virus infection significantly increases the mRNA expression of the proinflammatory cytokines such as IL-6 or CCL2 [36] . Urinary CCL2:Cr occurs to be a strong predictor of BKV nephropathy, but this was mentioned before in one paper only [37] . Recent studies on animal models indicate that CCL2 is critical mediator of chronic renal injury. In mice with renovascular hypertension CCL2 deficiency reduced the number of infiltrating mononuclear cells and expression of other proinflammatory cytokines. Those mice showed less cortical atrophy than wild type mice [38, 39] . Mao and Wu showed that specific genotype CCL2 carriers are at higher risk of developing chronic kidney disease [40] . We suggest that the role of CCL2 in immunocompromised transplant recipients especially with BK infection should be further studied. In our study CCL2:Cr does not seem to be a predictor of IFTA II-III or mild inflammatory lesions which is different from previous research [41, 42] . It is possible that the study was performed too early and the pathological changes in kidney allograft were not advanced enough.
According to our study CXCL10:Cr does not differentiate the research group from the control group. However, it correlates with eGFR, albuminuria and total HLA mismatch. It is reported that CXCL10:Cr is crucial in the initiation and development of acute rejection accompanying T-cell recruitment [43, 44] . In our research CXCL10:Cr is not a predictor of lesions associated with mild inflammatory reaction. The explanation could be that, regarding our patients, those processes developed more chronically without evident production of CXCL10. This could be confirmed by the fact that BK virus infection is an acute inflammation state and in our study it is associated with CXCL10:Cr. Similar results were obtained by other researchers [45, 46] . Using bioinformatics methods Jia et al. discovered that CXCL10 is one of hub proteins in the pathogenesis of BKV nephropathy. It promotes inflammation and prohibits reparation of tissue damage [47] . Lately, Popik et al, showed that BKV may induce CXCL10 in podocytes and mesangial cells which could contribute to fibrosis in BKV nephropathy and enhance glomerular inflammation [48] .
This study has some major limitations as it is single-center and includes relatively small study population. The number of patients with BKV nephropathy is low and no definitive conclusion can be stated. Abbreviations: BKV, BK virus; CCL2:Cr, chemokine CCL2-to-creatinine ratio ;CXCL10:Cr, chemokine CXCL10-to-creatinine ratio; IFTA, interstitial fibrosis and tubular atrophy Abbreviations: CCL2:Cr, chemokine CCL2-to-creatinine ratio; CXCL10:Cr, chemokine CXCL10-to-creatinine ratio; eGFR, estimated glomerular filtration rate; HLA, human leukocyte antigen 
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Multivariate logistic regression analysis includes CCL2:Cr and CXCL10:Cr as covariates.
Abbreviations: BKV, BK virus; CCL2:Cr, chemokine CCL2-to-creatinine ratio; CI, confidence interval; CXCL10:Cr, chemokine CXCL10-to-creatinine ratio; IFTA, interstitial fibrosis and tubular atrophy; OR, odds ratio
